SCHEMBL298155

SCHEMBL298155

CC(CCN1CCC(NS(C)(=O)=O)CC1)(C(=O)NCc1ccc(OC(F)(F)F)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DDR1 Q08345 4/20 0.43
TACR3 P29371 4/20 0.42
TACR2 P21452 3/20 0.42
TACR1 P25103 3/20 0.42
HTR2C P28335 1/20 0.41
EPHX2 P34913 3/20 0.40
NR1H4 Q96RI1 2/20 0.40
BCHE P06276 2/20 0.40
ACHE P22303 2/20 0.40
BACE1 P56817 2/20 0.40
TRPV1 Q8NER1 1/20 0.40
CCR2 P41597 1/20 0.39
SCN7A Q01118 1/20 0.39
SCN5A Q14524 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
MAPT P10636 1/20 0.38
KCNH2 Q12809 1/20 0.38
CACNA1I Q9P0X4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12943000 0.95 DDR1 (0.42) DDR1TACR3TACR2TACR1HTR2C
SCHEMBL296860 0.92 CARM1 (0.46) DDR1TACR3TACR2TACR1EPHX2
SCHEMBL296032 0.91 TACR3 (0.46) DDR1TACR3TACR2TACR1BCHE
SCHEMBL296022 0.90 TACR3 (0.43) TACR3TACR2TACR1EPHX2HRH3
SCHEMBL8034347 0.89 TACR3 (0.42) TACR3TACR2TACR1EPHX2CCR2
SCHEMBL297799 0.88 TACR3 (0.49) DDR1TACR3TACR2TACR1EPHX2
SCHEMBL298428 0.87 TACR3 (0.45) TACR3TACR2TACR1TRPV1HRH3
SCHEMBL299660 0.87 TACR3 (0.44) TACR3TACR2TACR1CCR2KCNH2
SCHEMBL3856595 0.87 EPHX2 (0.42) TACR3TACR2TACR1HTR2CEPHX2
SCHEMBL297584 0.87 TACR3 (0.43) TACR3TACR2TACR1CCR2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200982-B1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-03-14 EP disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 DDR1 1076/4885TACR3 95/4885TACR2 21/4885
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 DDR1 1076/4885TACR3 95/4885TACR2 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.